Saturday, 31 October 2026European Markets

JACQUES BOGART And UNIBEL Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(vianews) - jacques bogart (jbog.pa) is among this list of stock assets with the highest dividend rate and return on equity on the consumer defensive sector.

financial asset price forward dividend yield return on equity
jacques bogart (jbog.pa) €6.70 3.03% 7.12%
unibel (unbl.pa) €965.00 1.12% 6.65%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. jacques bogart (jbog.pa)

3.03% forward dividend yield and 7.12% return on equity

jacques bogart s.a. produces and sells fragrances and cosmetics in paris and internationally. the company markets its fragrance products under the jacques bogart, carven, chevignon, and ted lapidus brand names; cosmetic products under the stendhal, methode jeanne piaubert, and april brand names; and fashion products under the ted lapidus fashion brand name. jacques bogart s.a. was founded in 1975 and is based in paris, france.

earnings per share

as for profitability, jacques bogart has a trailing twelve months eps of €-0.61.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.12%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, jacques bogart's stock is considered to be overbought (>=80).

yearly top and bottom value

jacques bogart's stock is valued at €6.70 at 02:30 est, way under its 52-week high of €8.06 and way higher than its 52-week low of €5.44.

more news about jacques bogart.

2. unibel (unbl.pa)

1.12% forward dividend yield and 6.65% return on equity

unibel s.a. produces and sells cheese products in france. the company was incorporated in 1921 and is headquartered in paris, france.

earnings per share

as for profitability, unibel has a trailing twelve months eps of €43.04.

pe ratio

unibel has a trailing twelve months price to earnings ratio of 22.42. meaning, the purchaser of the share is investing €22.42 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.65%.

volume

today's last reported volume for unibel is 2 which is 50% below its average volume of 4.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, unibel's stock is considered to be overbought (>=80).

yearly top and bottom value

unibel's stock is valued at €965.00 at 02:30 est, under its 52-week high of €1,040.00 and way above its 52-week low of €795.00.

more news about unibel.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com